PureTech Health plc (PTCHF)
OTCMKTS · Delayed Price · Currency is USD
1.705
+0.005 (0.29%)
At close: Dec 29, 2025
PureTech Health Employees
PureTech Health had 56 employees as of December 31, 2024. The number of employees decreased by 34 or -37.78% compared to the previous year.
Employees
56
Change (1Y)
-34
Growth (1Y)
-37.78%
Revenue / Employee
$114,125
Profits / Employee
$904,964
Market Cap
413.54M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 56 | -34 | -37.78% |
| Dec 31, 2023 | 90 | -21 | -18.92% |
| Dec 31, 2022 | 111 | 16 | 16.84% |
| Dec 31, 2021 | 95 | -155 | -62.00% |
| Dec 31, 2020 | 250 | -50 | -16.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Glass House Brands | 374 |
| Silence Therapeutics | 116 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| OpGen | 1 |
PureTech Health News
- 13 days ago - PureTech Health (PRTC) Appoints Robert Lyne as CEO - GuruFocus
- 13 days ago - PureTech Health Appoints Robert Lyne As CEO; Focuses On Financing For Celea, Gallop Oncology - Nasdaq
- 13 days ago - PureTech Appoints Robert Lyne as Chief Executive Officer - Business Wire
- 23 days ago - PureTech Health (PRTC) Sets Stage for Key Phase 3 Trial with FDA Approval - GuruFocus
- 23 days ago - PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis - Business Wire
- 25 days ago - PureTech's Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Business Wire
- 2 months ago - PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group - Business Wire
- 3 months ago - Pres. Trump's deal with Pfizer is pretty devastating to PBMs and insurance companies: John Lamattina - CNBC